

Advent Pharma Ltd.
Statement of Financial Position (un-audited)
As at March 31, 2020

Particulars	Notes	Amount in Taka	
		31-Mar-2020	30-Jun-2019
ASSETS			
NON-CURRENT ASSETS		1,086,818,843	931,180,917
Property, Plant and Equipment	4.00	876,048,677	844,729,863
Capital Work in Progress (Building Construction)	5.00	210,770,166	86,451,054
CURRENT ASSETS		260,067,274	276,465,072
Inventories	6.00	83,244,367	70,810,152
Trade and Other Receivable		102,105,635	78,850,747
Advances, Deposits and Pre-payments		28,108,322	38,061,290
Cash and Cash Equivalents	7.00	46,608,950	88,742,883
Total Assets		1,346,886,117	1,207,645,989
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY		1,119,408,361	1,018,634,442
Share Capital	8.00	830,060,000	754,600,000
Retained Earnings	9.00	289,348,361	264,034,442
NON-CURRENT LIABILITIES		98,323,069	86,113,884
Long Term Borrowings - Net of Current Portion		16,127,287	19,114,798
Deferred Tax Liabilities	10.00	82,195,782	66,999,086
CURRENT LIABILITIES		129,154,687	102,897,663
Current Portion of Long Term Borrowings		7,912,963	7,912,963
Payable to IPO Applicants		109,355	129,355
Short Term Borrowings		17,038,725	7,235,622
Trade and other payables		23,240,687	12,630,812
Liabilities for expenses		5,554,290	4,083,317
Liability for contribution to WPPF		11,290,818	11,982,914
Provision for Current Tax	11.00	64,007,849	58,922,680
Total Liabilities		227,477,756	189,011,547
Total Shareholders' Equity and Liabilities		1,346,886,117	1,207,645,989
Net Asset Value (NAV) per Share	19.00	13,49	13,50

Company Secretary Chief Financial Officer Director Managing Director Chairman

Dated: June 24, 2020

Place: Dhaka

Advent Pharma Ltd.
Statement of Profit or Loss and Other Comprehensive Income (un-audited)
For the Period from 01 July, 2019 to 31 March, 2020

Particulars	Notes	Amount in Taka		Amount in Taka	
		July 01, 2019 to March 31, 2020	July 01, 2018 to March 31, 2019	Jan. 01, 2020 to March 31, 2020	Jan. 01, 2019 to March 31, 2019
A Revenues		476.704.605	489.320.034	144.782.408	159.412.446
B Cost of Sales	12.00	(269.217.022)	(257.233.073)	(95.503.758)	(84.050.376)
C Gross Profit		207.487.583	232.086.961	49.278.650	75.362.070
Operating Expenses		(49.559.965)	(43.064.881)	(21.337.700)	(13.289.909)
D Administrative expenses	13.00	(20.314.443)	(17.731.038)	(9.508.615)	(4.992.206)
Selling & Marketing Expenses	14.00	(29.245.522)	(25.333.843)	(11.829.085)	(8.297.703)
E Operating Profit		157.927.618	189.022.080	27.940.950	62.072.161
Non Operating Expenses		(3.704.681)	(4.619.462)	(1.347.568)	(1.375.961)
F Financial Expenses	15.00	(3.704.681)	(4.619.462)	(1.347.568)	(1.375.961)
G Other Income	16.00	9.289.943	6.159.318	2.464.540	3.036.392
H Loss on disposal on Fixed Assets	17.00	-	(1.662.857)	-	-
I Profit Before W.P.P.F		163.512.880	188.899.079	29.057.922	63.732.592
J Expenses for W.P.P.F		(7.786.328)	(8.995.194)	(1.383.711)	(3.034.885)
K Profit Before Tax		155.726.552	179.903.885	27.674.211	60.697.707
L Income Tax Expenses		(39.860.633)	(45.908.844)	(7.165.007)	(15.795.006)
Current Tax	11.00	(24.663.936)	(35.967.978)	(388.166)	(9.713.541)
Deferred Tax	10.00	(15.196.696)	(9.940.867)	(6.776.840)	(6.081.466)
M Net Profit After Tax		115.865.919	133.995.040	20.509.205	44.902.700
N Other Comprehensive Income		-	-	-	-
O Total Comprehensive income		115.865.919	133.995.040	20.509.205	44.902.700
P Earnings per Share (EPS)	18.00	1,40	1,61	0,25	0,54

Company Secretary

Chief Financial Officer

Director

Managing Director

Chairman

Dated: June 24, 2020

Place: Dhaka

Advent Pharma Ltd.
Statement of Changes in Equity (un-audited)
For the Period from 01 July, 2019 to 31 March, 2020

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2019	754.600.000	264.034.442	1.018.634.442
Net Profit for the period	-	115.865.919	115.865.919
Stock Dividend (2018-2019)	75.460.000	(75.460.000)	-
Cash Dividend (2018-2019)	-	(15.092.000)	(15.092.000)
Balance as on March 31, 2020	830.060.000	289.348.361	1.119.408.361

Advent Pharma Ltd.
Statement of Changes in Equity (un-audited)
For the Period from 01 July, 2018 to 31 March, 2019

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2018	686.000.000	187.950.804	873.950.804
Net Profit for the period	-	133.995.040	133.995.040
Stock Dividend (2017-2018)	68.600.000	(68.600.000)	-
Cash Dividend (2017-2018)	-	(13.720.000)	(13.720.000)
Balance as on March 31, 2019	754.600.000	239.625.844	994.225.844

Company Secretary Chief Financial Officer Director Managing Director Chiarkan

Dated: June 24, 2020
Place: Dhaka

Advent Pharma Ltd.
Statement of Cash Flows (un-audited)
For the Period from July 01, 2019 to March 31, 2020

Particulars	Amount in Taka	
	July 01, 2019 to March 31, 2020	July 01, 2018 to March 31, 2019
A. CASH FLOWS FROM OPERATING ACTIVITIES:		
Cash Receipts from Customers & Others	462.739.660	465.934.263
Cash Paid to Suppliers	(240.979.668)	(224.795.960)
Cash paid to Employees	(39.785.792)	(33.683.972)
Cash paid to Others	(32.444.277)	(35.892.373)
Tax Paid During This period	(5.925.368)	-
Net cash generated from operating activities	143.604.555	171.561.958
B. CASH FLOWS FROM INVESTING ACTIVITIES:		
Paid for Acquisition of Property, Plant & Equipment	(55.584.347)	(18.661.363)
Paid for Capital Work -in- Progress (construction)	(125.055.112)	(208.413.572)
Proceeds from disposal of Fixed Assets	-	250.767
Advance LC margin for Laboratory Equipment	-	(33.214)
Net cash used for investing activities	(180.639.459)	(226.857.382)
C. CASH FLOWS FROM FINANCING ACTIVITIES:		
Short Term Borrowings- Received/(Payment)	9.803.103	(15.805.283)
Long Term Borrowings-Received/(Payment)	(2.987.511)	(3.872.778)
Financial Expenses Paid	(3.463.732)	(4.459.790)
Cash Dividend Paid	(8.430.888)	(4.935.278)
Refund to IPO Applicants	(20.000)	(295.035)
Net cash used for financing activities	(5.099.028)	(29.368.164)
D. Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	(42.133.933)	(84.663.588)
E. Cash & Cash equivalents at the beginning of the period	88.742.883	186.393.813
F. Cash & Cash equivalents at the end of the period (D+E)	46.608.950	101.730.225
G. Net Operating Cash Flows Per Share	1,73	2,07

Company Secretary Chief Financial Officer Director Managing Director Chiarman

Dated: June 24, 2020
Place: Dhaka

Advent Pharma Limited

**Notes, comprising a summary of significant accounting policies and other explanatory information
as at and for the period ended 31 March-2020**

1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under The Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016. The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhamrai, Dhaka, Bangladesh.

2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

3.00 Basis of preparation and significant accounting policies

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities Exchange Rules 1987 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the period.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant & Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial Instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segment
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts with Customers

		Amount in Taka		
		31-Mar-2020	30-Jun-2019	
4.00	Property, Plant and Equipment			
	A. Cost			
	Opening Balance	927,415,596	648,882,223	
	Add: Addition during the period	55,665,253	280,723,373	
	Less: Disposal during the period	-	(2,190,000)	
		983,080,849	927,415,596	
	B. Accumulated Depreciation			
	Opening Balance	82,685,733	58,329,267	
	Add: Depreciation charged during the period	24,346,439	24,632,842	
	Less: Adjustment during the period	-	(276,376)	
		107,032,172	82,685,733	
	Written down Value (A-B)	876,048,677	844,729,863	
Details are shown in Annexure-A.				
5.00	Capital Work In Progress (Building Construction)			
	Opening Balance	86,451,054	94,733,366	
	Addition during the period	124,319,112	240,757,598	
	Transfer to Factory Building	-	(249,039,910)	
	Closing Balance	210,770,166	86,451,054	
6.00	Inventories			
	Finished Goods (Note-12.00)	35,565,820	22,786,458	
	Raw Materials	29,410,245	27,308,790	
	Packing Materials	7,855,102	6,779,356	
	Spare Parts	147,520	388,658	
	Work In Process (Note-12.00)	10,265,680	13,546,890	
		83,244,367	70,810,152	
7.00	Cash & Cash Equivalents			
	Cash in hand (Note-7.01)	153,371	231,781	
	Cash at bank (Note-7.02)	46,455,579	88,511,102	
	Total	46,608,950	88,742,883	
7.01	Cash in Hand			
	Head Office	81,672	207,370	
	Depots	71,699	24,411	
		153,371	231,781	
Cash in hand has been certified by the management of the company.				
7.02	Cash at Bank	46,455,579	88,511,102	
7.02.01	Cash at Bank			
	Bank Name			
	Islami Bank Bangladesh Ltd.	A/C No. # 283517	183,409	72,830
	Dutch Bangla Bank Ltd.	A/C No. # 129775	468,192	1,134,212
	Janata Bank Ltd	A/C No. # 10035785	216,675	173,198
	IFIC Bank Ltd.	A/C No. # 327-041	5,174,832	5,338,665
	IFIC Bank Ltd.	A/C No. # 327-001	43,523	1,275,496
	IFIC Bank Ltd.	A/C No. # 327-003	164,188	126,750
	Shahjalal Islami Bank Ltd.	A/C No. # 000-7339	23,155	165,794
	Midland Bank Ltd.	A/C No. # 000-6230	4,659	91,149
	BRAC Bank Ltd.	A/C No. # 150001	92,974	104,122
	BRAC Bank Ltd.	A/C No. # 150002	83,972	28,885
	Total	6,455,579	8,511,102	
7.02.02	Fixed Deposit Receipt (FDR)			
	Name of Financial Institution			
	Midland Bank Ltd.	FDR No.: 0019761	40,000,000	40,000,000
	Phoenix Finance & Investments Ltd.	TDR No.: 23977/18	-	30,000,000
	IFIC Bank Ltd.	FDR No.: 1299962	-	10,000,000
	Total		40,000,000	80,000,000
8.00	Share Capital			
	Authorized Capital :			
	100,000,000 ordinary shares of Tk. 10.00 each		1,000,000,000	1,000,000,000
	Issued, Subscribed & Paid-up Capital :			
	754,60,000 ordinary shares of Tk. 10.00 each		830,060,000	754,600,000
	830,06,000 ordinary shares of Tk. 10.00 each			

Share holding position of Shareholders:

Category of Shareholders	Number of Share Holding		Percentage of Share Holding		Amount in Taka	
	31-Mar-20	30-Jun-19	31-Mar-20	30-Jun-19	31-Mar-20	30-Jun-19
Director & Sponsor	26,096,675	23,724,250	31.44%	31.44%	260,966,750	237,242,500
Institutional	16,426,887	14,920,238	19.79%	19.77%	164,268,874	149,202,380
Public	40,482,438	36,815,512	48.77%	48.79%	404,824,376	368,155,120
Total	83,006,000	75,460,000	100%	100%	830,060,000	754,600,000

9.00 Retained Earnings

Balance brought forward
Add: Profit for the period
Stock Dividend
Cash Dividend
Balance carried forward

Amount in Taka	
31-Mar-2020	30-Jun-2019
264,034,442	187,950,804
115,865,919	158,403,638
(75,460,000)	(68,600,000)
(15,092,000)	(13,720,000)
289,348,361	264,034,442

10.00 Deferred Tax Liabilities

Opening Balance
Add: Provision made during the period (Note-10.01)
Closing Balance

66,999,086	43,259,181
15,196,696	23,739,905
82,195,782	66,999,086

10.01 Deferred tax liabilities as at March 31, 2020 is arrived as follows :

Written Down Value of PPE as per Accounting Base
Adjustment of WPPF
Written Down Value Considering WPPF
Written Down Value as per Third Schedule
Net Temporary Difference
Income Tax Rate
Deferred Tax Liability
Opening Deferred Tax Liability
Deferred Tax Expenses

876,048,677	844,729,863
(11,290,818)	(11,982,914)
864,757,859	832,746,948
(535,974,731)	(564,750,605)
328,783,128	267,996,343
25%	25%
82,195,782	66,999,086
(66,999,086)	(43,259,181)
15,196,696	23,739,905

11.00 Provision for Current Tax

Opening Balance
Add: Provision for tax during the period (Note-11.01)
Less: Paid during the period/Adjustment
Total

Amount in Taka	
58,922,680	29,105,618
24,663,936	29,817,062
(19,578,767)	-
64,007,849	58,922,680

11.01 Provision for Tax during the period

Accounting Profit before Tax
Add: Other Inadmissible Allowances
Accounting Depreciation
Provision for WPPF
Other Income
Loss on disposal of Fixed Assets
Less: Items for Separate Consideration
Depreciation as per 3rd Schedule
Payment for WPPF
Loss as per Third Schedule
Total Taxable Income
Rate
Total Tax Expenses/Current Tax
Tax on other income
Adjustment for previous year:
For the Income year 2013
For the Income year 2014
For the Income year 2015
For the Income year 2016(Jan.-June)
Total Tax Payable

155,726,552	211,960,605
24,346,439	24,632,842
7,786,328	10,598,030
(9,289,943)	(6,935,771)
-	1,662,857
(84,441,127)	(125,459,940)
(8,478,424)	(4,730,551)
-	(395,091)
85,649,825	111,332,981
25%	25%
21,412,456	27,833,245
3,251,480	2,427,520
-	(2,127,626)
-	2,129,756
-	1,799,178
-	(2,245,010)
24,663,936	29,817,062

12.00 Cost of Sales				
Raw Materials Consumed	232,922.903	220,823.619	82,215.360	71,888.949
Manufacturing Overhead (Note-12.01)	46,900.121	39,578.618	15,639.015	12,167.289
	279,823.024	260,402.237	97,854.375	84,056.238
Add: Opening Work in process	13,546.890	14,274.867	10,625.362	12,529.369
Less: Closing Work in process	(10,265.680)	(12,265.680)	(10,265.680)	(12,265.680)
Cost of Goods manufactured	283,104.234	262,411.424	98,214.057	84,319.927
Add: Opening stock of finished Goods	22,786.458	19,265.698	33,254.673	23,620.725
Cost of Goods Available for Sale	305,890.692	281,677.122	131,468.730	107,940.652
Less: Closing stock of finished Goods	(35,565.820)	(23,565.820)	(35,565.820)	(23,565.820)
Less: Sample Distribution	(1,107.850)	(878.229)	(399.152)	(324.456)
Cost of Sales	269,217.022	257,233.073	95,503.758	84,050.376

12.01 Manufacturing Overhead

Wages and Salary	8,956.055	7,859.097	3,238.770	2,562.458
Festival Bonus	526.777	440.500	-	-
Overtime	1,101.758	1,214.000	243.108	61.190
Packaging Materials Consumed	7,209.012	6,194.868	2,364.219	2,066.469
Spare Parts Consumed	1,425.303	2,198.955	622.752	720.180
Repair & Maintenance	639.148	949.263	83.859	320.540
Electricity Bill	1,044.636	1,279.150	231.260	340.778
Disel & Fuel	710.288	710.948	273.788	113.100
Electric & Sanitary Goods	393.700	498.202	46.938	19.784
Fire Insurance Premium	112.314	75.786	43.527	25.263
Canteen Expenses	1,169.954	960.234	303.569	195.003
Laboratory Expenses	188.633	325.220	126.790	86.520
Cleaning & Washing	218.351	98.571	168.657	20.308
Internet bill	20.400	21.700	7.500	7.500
Mobile & Telephone bill	20.870	25.350	8.420	8.250
Uniform	88.103	136.860	35.230	45.225
Depreciation (Annexure-A)	23,074.819	16,589.914	7,840.628	5,574.721
Total	46,900.121	39,578.618	15,639.015	12,167.289

13.00 Administrative Expenses

Salary & Allowance	8,537.982	8,773.779	2,943.067	2,885.979
Director Remuneration (Note # 22.01)	900.000	900.000	300.000	300.000
Conveyance	253.165	150.718	42.539	53.617
Subscription, Gift & Donation	56.200	88.300	36.650	8.800
Festival Bonus	319.550	487.550	-	-
Office Rent including VAT	517.500	517.500	172.500	172.500
Board meeting attendance fees (Note # 22.01)	180.000	270.000	45.000	45.000
Cleaning & Sanitation	22.695	87.011	8.927	9.819
Credit Rating Fee	50.000	50.000	-	-
Electricity Bill	132.024	62.436	29.197	11.729
Entertainment	395.128	546.211	204.542	167.252
Garage Rent	19.000	12.500	5.400	-
Legal, License & Renewal & Professional fee	1,949.823	419.665	1,552.156	68.034
Research & Product Development	2,230.000	516.000	2,225.375	59.850
Miscellaneous Expense	1,117.268	1,351.228	466.250	322.080
Newspaper & Magazine	4.136	6.523	850	2.662
Postage, Stamps & Courier	45.916	58.118	12.455	19.488
Printing & Stationery	437.229	551.857	189.575	71.062
Office Maintenance	176.940	182.972	63.830	68.200
Traning Allowance	17.760	59.760	5.760	5.760
Vehicle Repair & Maintenance	659.767	147.491	545.810	21.670
Fuel & Gas	321.930	531.293	88.653	154.146
Telephone & Mobile	170.165	84.552	39.519	24.114
Internet bill	82.000	65.700	27.000	21.000
Annual General Meeting Expenses	274.145	328.815	-	-
Audit Fees Inclundind VAT	172.500	172.500	57.500	57.500
Depreciation (Annexure-A)	1,271.620	1,308.559	446.060	441.944
Total	20,314.443	17,731.038	9,508.615	4,992.206

14.00 Selling & Marketing Expenses

Salary & Allowance	10,543.424	9,709.370	4,047.907	3,252.810
Travelling & Conveyance	4,758.217	4,136.707	2,103.860	1,385.533
Festival Bonus	466.935	528.785	-	-
Advertisement	106.498	277.205	31.400	25.550
Marketing Promotion	4,686.752	3,400.528	1,977.595	1,166.084
Distribution Cost	7,575.846	6,403.019	3,269.171	2,143.270
Sample Distribution	1,107.850	878.229	399.152	324.456
Total	29,245.522	25,333.843	11,829.085	8,297.703

15.00 Financial Expenses

Bank Charges	267.235	294.951	89.833	140.815
Interest on Loan	3,437.446	4,324.511	1,257.735	1,235.146
Total	3,704.681	4,619.462	1,347.568	1,375.961

16.00 Other Income

Interest on FDR	8,487.500	4,141.792	2,387.500	3,036.392
Bank Interest	203.666	567.074	-	-
Sales of Wastage(Others)	598.777	1,450.452	77.040	-
Total	9,289.943	6,159.318	2,464.540	3,036.392

17.00 Other Loss

Loss on disposal of Fixed Assets	-	1,662.857	-	-
Total	-	1,662.857	-	-

18.00 Basic Earnings Per Share

Profit after tax
Weighted average number of ordinary shares outstanding
Basic Earnings per Share(Re-stated 31 March, 2019)

Nine Month Ended		Quarterly Product	
31-Mar-2020	31-Mar-2019	31-Mar-2020	31-Mar-2019
115,865,919	133,995,040	20,509,205	44,902,700
83,006,000	83,006,000	83,006,000	83,006,000
1.40	1.61	0.25	0.54

Diluted Earnings Per Share

There is no condition for dilution during the period. No diluted EPS has been calculated.

This has been calculated in compliance with the requirements of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding the end of the period.

18.01 Calculation of Weighted Average Number of Shares as on March 31, 2020

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Nine Month Ended Product (Weighted Average)	Quarterly Product (Weighted Average)
					31-Mar-2020	31-Mar-2020
Shares at beginning	75,460,000	July-19 to March-20	275	20,751,500,000	75,460,000	75,460,000
Stock Dividend @ 10%	7,546,000	July-19 to March-20	275	6,860,000	7,546,000	7,546,000
Total	83,006,000			20,758,360,000	83,006,000	83,006,000

18.02 Calculation of Weighted Average Number of Shares as on March 31, 2019

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Nine Month Ended Product (Weighted Average)	Quarterly Product (Weighted Average)
					31-Mar-2019	31-Mar-2019
Shares at beginning	68,600,000	July-18 to March-19	275	18,865,000,000	68,600,000	68,600,000
Stock Dividend @ 10% -	6,860,000	July-18 to March-19	275	1,886,500,000	6,860,000	6,860,000
Stock Dividend @ 10% -	7,546,000	July-18 to March-19	275	2,075,150,000	7,546,000	7,546,000
Total	83,006,000		275	22,826,650,000	83,006,000	83,006,000

19.00 Net Asset Value (NAV) per Share

Total Asset
Less: Total outside Liability
Net Asset
Number of ordinary shares outstanding
Net Assets Value (NAV) per Share

31-Mar-2020	30-Jun-2019
1,346,886,117	1,207,645,989
227,477,756	189,011,547
1,119,408,361	1,018,634,441
83,006,000	75,460,000
13.49	13.50

20.00 Net Operating Cash Flows per Share(NOCFPS)

Net Cash Generated From Operating Activities
Weighted Average Number of Shares Outstanding
Net Operating Cash Flows per Share(NOCFPS)

31-Mar-2020	31-Mar-2019
143,604,555	171,561,958
83,006,000	83,006,000
1.73	2.07

21.00 Reconciliation of Net Profit with cash flows from Operating Activities:

Profit before Tax
Adjustment for:
Depreciation on property, plant and equipment
Financial Expenses
Loss on disposal of Fixed Assets

(Increase)/Decrease in Accounts Receivable
(Increase)/Decrease in Inventory
Less: Increase/(Decrease) in Trade and Other Payables
Add: Decrease/(Increase) in Advance, Deposit & Prepayments
Add: Increase in Liabilities for Expenses
Add: Increase in Liability for contribution to W.P.P.F

Less: Income Tax Paid
Net cash generated from operating activities

31-Mar-2020	31-Mar-2019
155,726,552	179,903,885
24,346,439	17,898,473
3,704,681	4,619,462
-	1,662,857
183,777,672	204,084,677
(23,254,888)	(29,545,089)
(12,434,215)	935,472
3,948,763	487,069
(3,045,337)	(9,818,601)
1,230,025	207,677
(692,096)	5,210,753
149,529,923	171,561,958
(5,925,368)	-
143,604,555	171,561,958

22.00 Related parties Transaction:

As per International Accounting standards IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

22.01 As per paragraph 17 of IAS 24: Disclosure of key management personnel compensation.**a) Short-term employee benefits :**

The amount of transaction for remuneration and board meeting fee during the period from 1st July 2019 to 31 st March 2020 are as follows:

Name	Designation	Remuneration	Board meeting fee
A.K.M. Shafiqul Alam	Chairman	-	20.000
Wajhi Ahmed	Managing Director	900.000	20.000
Kazi Rina Alam	Director	-	20.000
Faria Binta Alam	Director	-	20.000
Md. Tazul Islam	Director	-	20.000
Mohammad Towhidul Isl	Nominee Director	-	20.000
Asif Iqbal Chowdhury	Nominee Director	-	20.000
Mohammed Salim	Independent Director	-	20.000
Shekh Karimuzzaman	Independent Director	-	20.000
Total		900.000	180.000

b) Post employment benefits: Nil**c) Other long term benefits: Nil****d) Termination benefits: Nil****e) Share-based payment: Nil****23.00 Significant Deviation**

Advent Pharma Ltd. is a Veterinary medicine producer. Due to COVID 19 pandemic, our sales have decreased and raw materials price has increased in the market for interruption of import. On the other hand carrying cost also has increased. In this year we got approval for another 17 new products from drug administration and Department of Live Stock Services. For this we have spend some amount of money for product development. All of this reasons net profit after tax has decreased , earning per share and Net operating cash flows per has also decreased in the same line.

Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at March 31, 2020

Annexure-A
(Amount in Taka)

Particulars	Cost				Depreciation					Written down value as on 31-March-2020
	Balance as on 01-July-2019	Addition during the period	Disposal during the period	Balance as on 31-March-2020	Rate of Dep.	Balance as on 01-July-2019	Charged during the period	Adjustment during the period	Balance as on 31-March-2020	
Land	3.783.816	-	-	3.783.816	0%	-	-	-	-	3.783.816
Land Development	9.454.530	-	-	9.454.530	2,5%	579.164	166.413	-	745.577	8.708.953
Factory Building	527.536.942	-	-	527.536.942	2,5%	21.301.784	9.491.909	-	30.793.693	496.743.249
Plant & Machinery	219.601.006	53.434.378	-	273.035.384	5%	32.200.835	8.583.491	-	40.784.326	232.251.058
Sub-Station	6.694.722	-	-	6.694.722	10%	2.263.127	332.370	-	2.595.497	4.099.225
Motor Vehicle	6.097.576	-	-	6.097.576	15%	2.682.804	384.162	-	3.066.966	3.030.610
Furniture & Fixture	6.625.880	1.416.005	-	8.041.885	10%	1.882.099	403.591	-	2.285.690	5.756.195
Solar Panel	2.004.740	-	-	2.004.740	10%	622.907	103.637	-	726.544	1.278.196
Generator	627.520	-	-	627.520	10%	304.838	24.201	-	329.039	298.481
Air Conditioner	3.807.120	447.000	-	4.254.120	5%	709.269	131.219	-	840.488	3.413.632
Office Equipment	6.063.443	367.870	-	6.431.313	10%	1.566.748	352.648	-	1.919.396	4.511.917
HVAC System	44.536.240	-	-	44.536.240	5%	6.184.506	1.438.190	-	7.622.696	36.913.544
Laboratory Equipment	51.322.810	-	-	51.322.810	5%	7.056.954	1.659.970	-	8.716.924	42.605.886
Product Development Equipment	20.725.781	-	-	20.725.781	5%	2.818.714	671.515	-	3.490.229	17.235.552
ETP	18.488.470	-	-	18.488.470	5%	2.497.870	599.648	-	3.097.518	15.390.952
Books & Journals	45.000	-	-	45.000	15%	14.114	3.475	-	17.589	27.411
Total	927.415.596	55.665.253	-	983.080.849		82.685.733	24.346.439	-	107.032.172	876.048.677

Balance as at June 30, 2019	648.882.223	280.723.373	2.190.000	927.415.596		58.329.267	24.632.842	276.376	82.685.733	844.729.863
------------------------------------	--------------------	--------------------	------------------	--------------------	--	-------------------	-------------------	----------------	-------------------	--------------------

Allocation of Depreciation:

Administrative cost	1.271.620
Factory cost	23.074.819
Total	24.346.439